Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.
|
Center for Strategic and International S...
Senator Ted Cruz of Texas discusses the ...
FOX Business host Larry Kudlow discusses...
Jay Goldberg, senior analyst at Seaport ...
Scott Devitt, Wedbush equity research an...
Novo Nordisk Chief Executive Officer Mik...
Renaissance Macro Research Head of Econo...
Bloomberg’s Caroline Hyde and Ed Ludlow ...
'The Big Money Show' breaks down the eco...
On this week's episode of CNBC Crypto Wo...
On today's episode of Bloomberg Business...
'The Big Money Show' discusses the Trump...
Palantir CTO Shyam Sankar explains how A...